Default company panoramic image

Indel Therapeutics Inc.

Indel Therapeutics is a biotechnology company developing new drugs to address the global health crisis caused by antibiotic resistance.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Vancouver, BC, Canada
  • Currency CAD
  • Founded August 2008
  • Employees 9
  • Website

Company Summary

Indel Therapeutics is focused on the discovery, development and commercialization of new antibiotics to address the global health crisis of antibiotic resistance and cure serious, life-threatening infections. These programs are based on Indel’s paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of drug targets for the treatment of infectious diseases.


  • Default avatar
    Michael Abrams
    Executive Chairman

    Dr. Abrams has more than 25 years of successful drug discovery and development experience. He was involved in the discovery and development of Mozobil, a stem cell mobilizer used for hematopoietic stem cell transplantation in cancer patients, and Cardiolite, Bristol-Myers Squibb heart-imaging agent, the largest selling radiopharmaceutical in the world. He was co-founder and CEO of AnorMED, which was acquired by Genzyme for $580M in 2006.

  • Default avatar
    Malcolm Kendall

    Mr. Kendall has over 25 years of operational management, entrepreneurial, venture capital investment and leadership experience, the majority of which has been focused on company creation and building value in technology and biotechnology companies. Formerly a life science venture capitalist with MDS Capital and Intersouth Partners, he also lectures at the Segal Graduate School of business, Simon Fraser University.

  • Default avatar
    Neil Reiner

    Dr. Reiner is an internationally recognized authority on host-pathogen interactions. He is a Professor & Research Director of the Division of Infectious Diseases in the Department of Medicine at the University of British Columbia and Vancouver General Hospital, where he was formerly Head of the Division of Infectious Diseases. He also serves as Director of Immunity and Infection Research Centre of the Vancouver Coastal Health Research Institute.

  • Default avatar
    Roger Leger
    Consulting VP of Research

    Dr. Léger has more than 16 years of R&D experience, mostly focused on the discovery and development of novel antibiotics. Prior to Indel, he was VP of Research at Ulysses Pharma, a company focused on discovering and developing novel antibiotics. Prior to this, Dr. Léger was Director of Chemistry at ConjuChem and a Research Fellow at Microcide, where he was involved in the discovery of antibacterial natural products and efflux pump inhibitors.


  • Default avatar
    McCarthy Tétrault LLP
    Default avatar
    Zielke & Company

Previous Investors

  • Default avatar
    Morningside Ventures, Quatum Pacific Capital, MAD Ventures
    Default avatar
    Al Collings, Julia Levy, Richard Glickman, Mike Abrams, Jack Wood
    Default avatar
    Chuck Fisher, and other angel investors